NCT01074411 2019-08-09Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerNational Cancer Institute (NCI)Phase 1 Completed33 enrolled